Cargando…

Opioid Treatment Patterns Following Prescription of Immediate-Release Hydrocodone

BACKGROUND: Immediate-release (IR) hydrocodone is the most widely prescribed opioid in the United States; however, little is known about the utilization patterns and duration of opioid use among patients prescribed IR hydrocodone. A better understanding of the use of IR hydrocodone would result in m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ben-Joseph, Rami, Bell, Jill A., Brixner, Diana, Kansal, Anuraag, Paramore, Clark, Chitnis, Abhishek, Holly, Pamela, S. Burgoyne, Douglas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397816/ https://www.ncbi.nlm.nih.gov/pubmed/27023689 http://dx.doi.org/10.18553/jmcp.2016.22.4.358

Ejemplares similares

Single- and multiple-dose pharmacokinetics of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) compared with immediate-release hydrocodone bitartrate/ibuprofen and immediate-release tramadol HCl/acetaminophen
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Opioid-related overdose and chronic use following an initial prescription of hydrocodone versus oxycodone
por: Weiner, Scott G., et al.
Publicado: (2022)

Patterns of abuse and routes of administration for immediate‐release hydrocodone combination products
por: Cassidy, Theresa A., et al.
Publicado: (2017)

Extended-release hydrocodone – gift or curse?
por: Krashin, Daniel, et al.
Publicado: (2013)

Quantification of Opioid Prescription Practice Changes Due to Hydrocodone Combination Product Rescheduling in an Academic Pain Clinic
por: Ngo, John, et al.
Publicado: (2020)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Comparison of single-dose and multiple-dose pharmacokinetics between two formulations of hydrocodone bitartrate/acetaminophen: immediate-release versus biphasic immediate-release/extended release
por: Devarakonda, Krishna, et al.
Publicado: (2015)

A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough
por: Sloan, Victor S., et al.
Publicado: (2019)

Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations
por: Gould, Harry J, et al.
Publicado: (2015)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

The Decline in Hydrocodone/Acetaminophen Prescriptions in Emergency Departments in the Veterans Health Administration Between 2009 to 2015
por: Grasso, Michael A., et al.
Publicado: (2016)

Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Darwish, Mona, et al.
Publicado: (2017)

Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
por: Bond, Mary, et al.
Publicado: (2018)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr, Stephen J, et al.
Publicado: (2015)

Hydrocodone, Oxycodone, and Morphine Metabolism and Drug–Drug Interactions
por: Coates, Shelby, et al.
Publicado: (2023)

Single-dose pharmacokinetics of 2 or 3 tablets of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen (MNK-155) under fed and fasted conditions: two randomized open-label trials
por: Devarakonda, Krishna, et al.
Publicado: (2015)

Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications
por: Chua, Kao-Ping, et al.
Publicado: (2021)

Prolonged Ventricular Asystole: A Rare Adverse Effect of Hydrocodone Use
por: Sudhakaran, Sivakumar, et al.
Publicado: (2014)

Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review
por: Cardia, Luigi, et al.
Publicado: (2018)

The Rise of Prescription Digital Therapeutics in Behavioral Health
por: Brezing, Christina A., et al.
Publicado: (2022)

Development of a New Type of Prolonged Release Hydrocodone Formulation Based on Egalet® ADPREM Technology Using In Vivo–In Vitro Correlation
por: Hemmingsen, Pernille H., et al.
Publicado: (2011)

Assessment of Alcohol-Induced Dose Dumping with a Hydrocodone Bitartrate Extended-Release Tablet Formulated with CIMA(®) Abuse Deterrence Technology
por: Darwish, Mona, et al.
Publicado: (2015)

Update on prescription extended-release opioids and appropriate patient selection
por: Brennan, Michael J
Publicado: (2013)

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
por: Kansal, Anuraag R., et al.
Publicado: (2021)

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States
por: Iwanicki, Janetta L., et al.
Publicado: (2016)

U.S. Pharmacist Opinions Regarding the Rescheduling of Hydrocodone Combination Products: A Pilot Study
por: Covvey, Jordan R., et al.
Publicado: (2015)

An Analysis of Oxycodone and Hydrocodone Distribution Trends in Delaware, Maryland, and Virginia Between 2006 and 2014
por: Eufemio, Conor M, et al.
Publicado: (2023)

A long-term, open-label safety study of single-entity hydrocodone bitartrate extended release for the treatment of moderate to severe chronic pain
por: Nalamachu, Srinivas, et al.
Publicado: (2014)

Real-world utilization of once-daily extended-release abuse deterrent formulation of hydrocodone: a comparison with the pre-approval randomized clinical trials
por: Taber, Louise, et al.
Publicado: (2017)

Impact of Online Prescription Management Systems on Biologic Treatment Initiation
por: Hawkes, Jason E., et al.
Publicado: (2019)

Payer perceptions on the use of economic models in oncology decision making
por: Biskupiak, Joseph, et al.
Publicado: (2021)

Patterns of Immediate-Release and Extended-Release Opioid Analgesic Use in the Management of Chronic Pain, 2003-2014
por: Hwang, Catherine S., et al.
Publicado: (2018)

Factors Associated With Opioid Overdose After an Initial Opioid Prescription
por: Weiner, Scott G., et al.
Publicado: (2022)

Safety profile of prophylactic rescue dosing of immediate-release oral opioids in cancer patients
por: Tanaka, Rei, et al.
Publicado: (2018)

Crowdsourcing Black Market Prices For Prescription Opioids
por: Dasgupta, Nabarun, et al.
Publicado: (2013)

Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review
por: Tetrault, Jeanette M., et al.
Publicado: (2015)

Effect Of A “No Superuser Opioid Prescription” Policy On ED Visits And Statewide Opioid Prescription
por: Kahler, Zachary P., et al.
Publicado: (2017)

Impact of prescription drug monitoring program mandate on postoperative opioid prescriptions in children
por: Theodorou, Christina M., et al.
Publicado: (2021)

Evaluating the stability of opioid efficacy over 12 months in patients with chronic noncancer pain who initially demonstrate benefit from extended release oxycodone or hydrocodone: harmonization of Food and Drug Administration patient-level drug safety study data
por: Farrar, John T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mdqo6u15foce8gtebqbpn6ijtc